黒色腫または非小細胞肺癌からの脳転移を有する患者に対する定位放射線手術を伴うまたは伴わない免疫療法または標的療法 (USZ-STRIKE)
転移性黒色腫または新たに診断された転移性NSCLCおよび無症候性または乏症の脳転移を有する患者に対する標準的な全身療法に加えて、定位放射線手術の多施設無作為化非盲検第III相研究
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Heidi Roschitzki-Voser, Dr.
- 電話番号:+41 31 511 94 18
- メール:heidi.roschitzki@etop.ibcsg.org
研究連絡先のバックアップ
- 名前:Susanne Roux
- 電話番号:+41 31 511 94 17
- メール:susanne.roux@etop.ibcsg.org
研究場所
-
-
-
London、イギリス
- 募集
- Royal Marsden (Sutton)
-
コンタクト:
- Mary O'Brian
- メール:mary.obrien@rmh.nhs.uk
-
Manchester、イギリス
- 募集
- Christie NHS Manchester
-
コンタクト:
- Sarah Hughes
- メール:sarah.hughes91@nhs.net
-
-
-
-
-
Naples、イタリア
- 募集
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
-
コンタクト:
- Paolo Ascierto
- メール:p.ascierto@istitutotumori.na.it
-
Padova、イタリア
- まだ募集していません
- Instituto Oncologico Veneto IRCCS
-
コンタクト:
- Luisa Piccin
- メール:luisa.piccin@iov.veneto.it
-
Perugia、イタリア
- 募集
- Santa Maria della Misericordia Hospital
-
コンタクト:
- Mario Mandala
- メール:mario.mandala@unipg.it
-
Roma、イタリア
- 募集
- Istituto Nazionale Tumori "Regina Elena"
-
コンタクト:
- Gabriele Minuti
- メール:gabriele.minuti@ifo.it
-
Rome、イタリア
- 募集
- Policlinico Umberto 1
-
コンタクト:
- Giuseppe Minniti
- メール:giuseppe.minniti@uniroma1.it
-
Siena、イタリア
- 募集
- Azienda ospedaliero-universitaria Senese Siena
-
コンタクト:
- Anna Maria di Giacomo
- メール:a.m.digiacomo@ao-siena.toscana.it
-
-
-
-
-
Amsterdam、オランダ
- 募集
- NKI-AVL
-
コンタクト:
- Paul Baas
- メール:p.baas@nki.nl
-
-
-
-
-
Bern、スイス
- 募集
- Inselspital
-
コンタクト:
- Ekin Ermis
- メール:ekin.ermis@insel.ch
-
Winterthur、スイス
- 募集
- Kantonsspital Winterthur
-
コンタクト:
- Natalie Fischer
- メール:natalie.fischer@ksw.ch
-
Zurich、スイス
- 募集
- Universitätsspital Zürich
-
コンタクト:
- Michael Weller, Prof.
- メール:Michael.Weller@usz.ch
-
-
-
-
-
Barcelona、スペイン
- 募集
- Vall Hebron Institute of Oncology (VHIO)
-
コンタクト:
- Patricia Irano
- メール:piranzo@vhio.net
-
Majadahonda、スペイン
- 募集
- Hospital Puerta de Hierro
-
コンタクト:
- Ana Collazo Lorduy
- メール:anaclorduy@gmail.com
-
Valencia、スペイン
- 募集
- Hospital La Fe
-
コンタクト:
- Oscar Jose Juan Vidal
- メール:juan_osc@gva.es
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Most important inclusion criteria:
-
Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.
-
Requirements for brain metastases:
-
Brain metastases must be previously untreated, except for surgery.
-
Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.
-
Number and size of metastases at diagnosis of brain metastases:
- Maximum 1-10 brain metastases at screening
- At least one brain metastasis must be of ≥5 mm in diameter
- In case of 1-4 brain metastases:
- Longest diameter of largest brain metastasis must be ≤30 mm
- In case of 5-10 brain metastases:
- Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
- Maximum cumulative brain metastases volume must be ≤30 mL
-
Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC
-
Requirements for patients with melanoma:
-
Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).
-
BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).
-
Requirements for patients with NSCLC:
-
Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.
-
Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)
-
Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).
-
Age of 18 years or older
-
Karnofsky performance status of 60 or more
-
Life expectancy >12 weeks
-
Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).
-
Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.
-
Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Most important exclusion criteria:
- Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
- Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
- Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
- Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
- Prior whole brain irradiation or focal radiation therapy to the brain
- Prior systemic treatment for brain metastases
- Contra-indication for SRS
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Standard systemic treatment with stereotactic radiosurgery (SRS)
Arm A |
Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of >20 mm or for >4 brain metastases. For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation. Systemic therapy follows the current standard of care, according to the type of the primary tumour.
他の名前:
|
|
アクティブコンパレータ:Standard systemic treatment without stereotactic radiosurgery
Arm B |
Systemic therapy follows the current standard of care, according to the type of the primary tumour.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CNS-specific PFS, locally assessed as per iRANO criteria
時間枠:from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy. |
from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
協力者と研究者
協力者
捜査官
- スタディチェア:Michael Weller, MD、University of Zurich
- スタディチェア:Rolf Stahel, MD、ETOP IBCSG Partners Foundation
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ETOP 19-21
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。